Popular Trials
Monoclonal Antibodies
MEDI6570 for Heart Attack
Recruiting0 awardsPhase 2
Torrance, CA
This trial is testing MEDI6570, a new medication that aims to reduce inflammation in people who have had a heart attack. The goal is to see if it can help prevent more heart problems. The study will help decide how to use this medication in future treatments.
Behavioral Intervention
Self-Contained Underwater Breathing Apparatus (SCUBA) without OT +1 More for Depression Treatment
Recruiting1 award4 criteria
Loma Linda, California
The purpose of the study is to investigate whether an occupational therapy program could enhance mental health outcomes for veterans who SCUBA dive. SCUBA diving requires modified breathing techniques and has been found to provide calming effects to individuals who engage in this activity. Occupational therapy interventions such as mindfulness, journaling, and deep breathing techniques can also provide similar calming effects. Therefore, this study will explore whether occupational therapy can provide additional benefits to overall mental health of veterans who SCUBA dive.
Placebo for Joint Pain
Recruiting1 awardPhase 3
Harbor City, California
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer. PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients with stage I, stage II, or stage III breast cancer receiving hormone therapy.
Serotonin-Norepinephrine Reuptake Inhibitor
Desvenlafaxine Succinate for Depression
Recruiting4 awardsPhase 3
Newport Beach, California
The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR) during open-label treatment in adult outpatients who had a primary diagnosis of major depressive disorder (MDD). The study also evaluated the long-term response of subjects receiving DVS SR for clinical global evaluation, functionality, general well-being, pain, and absence of depressive symptoms (remission).
Atypical Antipsychotic
Ziprasidone for Schizophrenia
Recruiting5 awardsPhase 4
Torrance, California
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.
Popular Filters
Phase 3 Trials
Antiretroviral
E/C/F/TAF +1 More for Antiretroviral Therapy
Recruiting3 awardsPhase 3
Torrance, California
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin +2 More for Type 2 Diabetes
Recruiting3 awardsPhase 3
Lomita, California
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Corticosteroid
Dexamethasone +2 More for Multiple Myeloma
Recruiting4 awardsPhase 3
Fountain Valley, California
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
Recruiting3 awardsPhase 3
Long Beach, California
This trial will study the long-term effects of dupilumab, a drug used to treat atopic dermatitis, in adults. The trial will also assess the immunogenicity of dupilumab and monitor its efficacy. There is also an optional sub-study that will assess the safety of a new dupilumab drug product and evaluate its systemic exposure and immunogenicity.
Trials With No Placebo
Monoclonal Antibodies
CF33-CD19 + Blinatumomab for Solid Cancers
Recruiting1 awardPhase 1
Duarte, California
This trial tests a new virus and an immune-boosting drug in adults with advanced cancers that haven't responded to other treatments. The virus aims to kill cancer cells directly, while the drug helps the immune system attack the cancer.
Insulin
Insulin Glargine +1 More for Type 2 Diabetes
Recruiting5 awardsPhase 4
Long Beach, California
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) \< 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents Secondary objectives of the comparative period (24 weeks): \>To assess the effect of insulin glargine in comparison with liraglutide on: * HbA1c level * Percentage of patients whose HbA1c has decreased but remains \>= 7% at the end of the comparative period * Percentage of patients whose HbA1c has increased at the end of the comparative period * Fasting Plasma Glucose (FPG) * 7-point Plasma Glucose (PG) profiles * Hypoglycemia occurrence * Body weight * Adverse events Objectives of the extension period (24 weeks): \>To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on: * HbA1c level * FPG * 7-point PG profiles * Hypoglycemia occurrence * Body weight * Adverse events
Behavioral Intervention
Women-Only for Addiction
Recruiting1 award4 criteria
Los Angeles, California
The purpose of this study is to determine whether substance abuse treatment designed specifically for drug-dependent women offenders provides better outcomes than standard drug court treatment (mixed-gender programs).
Corticosteroid
Dexamethasone +2 More for Multiple Myeloma
Recruiting4 awardsPhase 3
Fountain Valley, California
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.